Biofrontera Investor Relations Material

Biofrontera Inc. is a biopharmaceutical company based in the United States, engaged in the commercialization of pharmaceutical products designed to treat dermatological conditions. The company's focus is on photodynamic therapy (PDT) and topical antibiotics. Biofrontera's product portfolio includes Ameluz, a prescription drug for the treatment of actinic keratosis, a common precancerous skin condition, when used in combination with its BF-RhodoLED lamp. Another product, Xepi, is a topical cream approved for the treatment of impetigo, a bacterial skin infection. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the Nasdaq.